The rare cancer Network: Achievements from 1993 to 2012

Ajaykumar Patel, Mahmut Ozsahin, Rene Olivier Mirimanoff, Sumita Bhatia, Kenneth Chang, Robert Clell Miller

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


The Rare Cancer Network (RCN), founded in 1993, performs research involving rare tumors that are not common enough to be the focus of prospective study. Over 55 studies have either been completed or are in progress. The aim of the paper is to present an overview of the 30 studies done through the RCN to date, organized by disease site. Five studies focus on breast pathology, including sarcoma, lymphoma, phyllodes tumor, adenoid cystic carcinoma, and ductal carcinoma in situ in young women. Three studies on prostate cancer address prostatic small cell carcinoma and adenocarcinoma of young and elderly patients. Six studies on head and neck cancers include orbital and intraocular lymphoma, mucosal melanoma, pediatric nasopharyngeal carcinoma, olfactory neuroblastoma, and mucosa-associated lymphoid tissue lymphoma of the salivary glands. There were 4 central nervous system studies on patients with cerebellar glioblastoma multiforme, atypical and malignant meningioma, spinal epidural lymphoma and myxopapillary ependymoma. Outside of these disease sites, there is a wide variety of other studies on tumors ranging from uterine leiomyosarcoma to giant cell tumors of the bone. The studies done by the RCN represent a wide range of rare pathologies that were previously only studied in small series or case reports. With further growth of the RCN and collaboration between members our ability to analyze rare tumors will increase and result in better understanding of their behavior and ultimately help direct research that may improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)110-114
Number of pages5
JournalRare Tumors
Issue number3
StatePublished - 2012


  • Oncology
  • Radiotherapy
  • Rare
  • Tumors

ASJC Scopus subject areas

  • Histology
  • Oncology


Dive into the research topics of 'The rare cancer Network: Achievements from 1993 to 2012'. Together they form a unique fingerprint.

Cite this